Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Shares Outstanding (Weighted Average) (2024 - 2025)

Maze Therapeutics has reported Shares Outstanding (Weighted Average) over the past 2 years, most recently at $43.0 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1693.59% to $43.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.0 million through Dec 2025, up 1693.59% year-over-year, with the annual reading at $43.0 million for FY2025, 1693.59% up from the prior year.
  • Shares Outstanding (Weighted Average) was $43.0 million for Q4 2025 at Maze Therapeutics, down from $45.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $45.8 million in Q3 2025 and troughed at $2.3 million in Q1 2024.